ponatinib
FDA Grants Accelerated Approval to Iclusig With Chemotherapy for Newly Diagnosed Ph-positive ALL
The FDA granted accelerated approval to ponatinib (Iclusig, Takeda Pharmaceuticals U.S.A.) with chemotherapy for ...
MARCH 19, 2024
Ponatinib Shows Promise In Difficult-to-Treat CP-CML
Among patients with chronic-phase chronic myeloid leukemia who are resistant to treatment with second-generation ...
AUGUST 30, 2022
Iclusig Granted Approval and Label Update for CML
Ponatinib is fully approved to treat adult patients with chronic phase, accelerated phase, or blast phase chronic ...
NOVEMBER 29, 2016
Load more